Replies to post #107756 on Biotech Values

[DewDiligence]

Notwithstanding that there is no bona fide news until 2011, MRK’s reticence vis-à-vis TRA still strikes me as curious, especially when you consider the manifold problems they have elsewhere in their portfolio.